Cancer stem cells (CSCs) are naturally resistant to chemotherapy, explaining why tumor relapse frequently occurs after initial regression upon administration of chemotherapeutic agents in most cases. A CSC population characterized by CD13 expression has been identified in hepatocellular carcinoma (HCC). In the current study, we aimed to clarify the molecular mechanism by which it escapes conventional therapies.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer and the second most frequent cause of cancer death in men worldwide [1] . The treatment algorithms in the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC) guidelines recommend resection and ablation or transplantation for early stage HCC, transcatheter arterial chemoembolization (TACE) for intermediate-stage HCC and sorafenib for advanced-stage HCC [2, 3] . Unfortunately, cancer cells often develop chemoresistance, which presents a major obstacle to the long-term efficacy of chemotherapeutic treatments. There is increasing evidence that resistance to chemotherapy is, at least in part, caused by inherent resistance of a subpopulation of cancer cells, which have been labeled as CSCs [4] . Liver CSCs are considered to be responsible for tumor growth, metastasis and recurrence of HCC as well as for the failure of chemotherapy and radiotherapy [5] . The traditional strategies leave behind residual CSCs which possess the abilities of selfrenewal, multi-directional differentiation and indefinite proliferation, as well as high tumorigenic ability [4] , leading to cancer recurrence and metastasis. Therefore, the cancer stem cell theory offers novel insight into tumor diagnosis, treatment and prevention.
Several markers have been proposed in the literature to identify CSCs in HCCs using cell surface antigens [6, 7] . Recently, Haraguchi et al. [8] identified CD13, a membrane-bound zincdependent type II exopeptidase, as a candidate liver cancer stem cell marker by a surface marker screen based on microarray analysis [8] . CD13 + CSCs were enriched in side population, which 6 Korean Cancer Association This article is protected by copyright. All rights reserved. examine the metabolic phenotypes that render CD13 + CSCs multidrug-resistant in HCCs.
Materials and Methods

HCC cell lines.
Huh7 and HepG2 cells were were obtained from American Type Culture Collection and cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen). 
Flow cytometry and cell sorting
In vitro isotope labeling and kinetic profiling
To trace glucose, glutamine or tyrosine metabolism, CD13 + cells were grown as tumorspheres in growth media (DMEM/F12) on 10 cm dishes and then transferred into glucose-, glutamine-or Tyr-free DMEM/F12 medium supplemented with 13 C-glucose, 13 C-glutamine and 13 C-tyrosine (Cambridge Isotope Labs, Tewksbury, MA) to 10 mM (for glucose), 2 mM (for glutamine) or 0.1 mM (for Tyr) overnight (for steady-state labeling) or for the indicated time points in the flux analyses. Additionally, fresh media containing 13 C-glucose, 13 C-glutamine and 13 C-tyrosine was exchanged 2hr prior to metabolite extraction for steady state analyses.
Statistical analysis
All statistical analyses were carried out with SPSS (IBM Corp., Armonk, NY). ANOVA, Student's t test, and Dunnett's multiple comparison tests were used to compare mean values.
Data are presented as mean±SD. A p-value <0.05 was defined as statistically significant. Other methods are shown in Supplementary Methods
Ethics statement
Human HCC specimens were obtained with written informed consent from all subjects before surgery and in accordance with the ethical standards of the Institutional Review Board of HuaShan Hospital (No. 20170036). The collection and processing of all samples were carried out in accordance with the Declaration of Helsinki. All mouse experiments were conducted in accordance with standard operating procedures approved by the Institutional Animal Care and Korean Cancer Association This article is protected by copyright. All rights reserved.
Use Committee for Shanghai Public Health Clinical Center (protocol number: 2018X112) and adhered to the Animals in Research: Reporting In Vivo Experiments (ARRIVE) Guidelines.
Results
Quiescent CD13 + CSCs is selectively enriched following chemotherapy in HCCs
Analysis of HepG2 cells by flow cytometry showed that CD13cells were a majority (82.3%±6.9%) of the total population before treatment. However, the viable CD13-population was reduced to 15.3%±3.1% after exposure to 5-fluorouracil (5-FU; 5 μM) for 72 hours, while the viable CD13 + population increased from 8.4%±2.3% to 72.1%±5.2% (Fig. 1A, left) . Similar results were observed in HepG2 cells after exposure to sorafenib (SR, 4 μM) ( Fig. 1A, left) .
Immunoblotting further confirmed a significant enrichment for endogenous CD13 protein ( Fig.   1B ). Similarly, neither 5-FU nor sorafenib failed to eradicate all HCC cells and enriched for CD13 + cells in HuH7 (Fig. 1A, right and B). The quiescent state of CSCs is believed to protect them from therapeutic agents [14] . As compared with CD13cells, the matched CD13 + subpopulation expressed lower levels of markers for cell proliferation, including Ki67, proliferating cell nuclear antigen, and MCM2 (Fig. 1C ). Analysis of HepG2 and HuH7 cells using Hoechst plus pyroninY staining showed that >60% of CD13 + fraction were in the G0 phase. In contrast, most CD13fractions were actively cell cycling (<40% in the G0 phase) ( Fig.   1D ). In addition, we examined changes in CD13 staining in 9 HCC patients after receiving hepatic arterial infusion chemotherapy, using low-dose concomitant radiochemotherapy with 9 Korean Cancer Association This article is protected by copyright. All rights reserved. cisplatin (CDDP) and 5-FU with/without leucovorin. All patients initially achieved a partial regression to drug treatment. As compared to the pretreatment values, the score of CD13 staining was significantly increased in seven out of nine residual tumors ( Fig. 1E and F ).
Three-dimensional (3D) organoids serve as an excellent tool to recapitulate tumorigenic aspects and drug responses of advanced human carcinomas [15] . In the current study, we generated 3D organoids from therapy-naive patients with HCC. Briefly, single-cell suspensions from tumor biopsies were suspended in Matrigel with fully supplemented aDMEM/F12 + .
Spherical structures, which were defined as 3D organoids, were detected by day 7 and continued to grow to ~200 μm in diameter by day 14 (Fig. 1G ). We successfully generated 3D organoids from three of five tumors (60%), two (T3 and T4) of which could be passaged at least once to exhibit a continuous growth ( Fig. 1H ). Quantitative analysis demonstrated that the organoids harbored similar percentages of CD13 + cells when compared with the corresponding primary tumors ( Fig. 1I ). Moreover, the proportion of CD13 + cells remained relatively constant in organoids during serial passages ( Fig. 1J ), suggesting that organoids contain steady ratios of CSC populations in long-term cultures. Next, we evaluated the efficiency of organoid formation after treatment of chemotherapeutic agents. Upon administration of 5-FU or sorafenib, the efficiency of organoid formation decreased; this impairment remained unchanged along with serial passages of organoid culture (Fig. 1K ). More importantly, the frequency of CD13+ cells, as detected by fluorescence-activated cell sorting, was significantly increased in organoids following treatments of chemotherapeutic agents ( Fig. 1L ). Together, these data imply a universal chemoresistance of CD13 + CSCs in HCCs.
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Tyrosine metabolism is enhanced in CD13+CSCs from HCCs
In comparison with differentiated tumor cells, CSCs are more dependent on glycolysis [16] .
Unexpectedly, CD13 + cells had negligible glycolytic activity than the matched CD13counterpart (S1A Fig) . Glucose and glutamine are essential energy sources for cancer cells [17] .
Unlike CD13cells (S1B Fig) , however, deprivation of glucose or glutamine did not affect the viability of CD13 + fraction ( Fig. 2A ), suggesting a switch to alternative nutrient supply.
Removing essential nutrients, one at a time, revealed significant apoptosis upon deprivation of leucine, valine, and most notably tyrosine ( Fig. 2A ). Deprivation of phenylalanine, a precursor of Tyr, did not affect cell survival ( Fig. 2A ), due to deficiency of phenylalanine hydroxylase in these cells. A significant reduction of Tyr concentration in culture medium during 24hours incubation was observed in CD13 + but not CD13-cells ( Fig. 2B ). Tyr consumption by CD13 + cells was accompanied by higher expression of enzymes in Tyr degradation (TAT, HPD, HGD, MAAI and FAH) ( Fig. 2C ). Furthermore, we infused 13 The differential dependence on Tyr metabolism between CD13 + and CD13cells prompts us to explore the underlying mechanism(s). We examined whether CD13 is the key determinant for activation of tyrosine metabolism in CD13 + CSCs. Notably, metabolomic analysis using 13 C-Tyr tracing revealed that CD13 knockdown decreased Tyr uptake (S1D Fig the contrary, overexpression of CD13 in CD13cells recapitulated the metabolite phenotype observed in the CD13 + counterpart (Fig. 2F , S1F and S1G Fig) , highlighting the specificity of CD13 for metabolic switch in CD13 + subpopulation. Consistently, Tyr deprivation led to massive apoptosis in cultured CD13 + cells and spared >95% CD13fraction ( Fig. 2G ).
Targeting Tyr metabolism by Nitisinone ablates CD13+CSCs and postpones recurrence in HCCs
Since CD13 + CSCs in HCCs are Tyr addictive, we examined whether Tyr metabolism is an effective target for preventing tumor recurrence. As almost all enzymes in Tyr degradation were found differentially regulated in CD13 + CSCs, we explored shRNAs against TAT, HPD, HGD, MAAI and FAH in a series of preliminary cytotoxicity assays. Here, shRNA against HPD revealed the most prominent results (Fig. 3A) ; thus, HPD was selected for subsequent studies. Nitisinone, a commercial safe drug licensed for treatment of hereditary tyrosinaemia, can interrupt tyrosine metabolism through inhibition of HPD [18] ; it was prioritized for followup. Firstly, we evaluated the in vitro sensitivity of CD13 + cells to Nitisinone. Cytotoxicity assays confirmed a dramatic targeting of CD13 + cells with much less effect in CD13compartment ( a single pulse of Nitisinone plus 5-FU over 72 hours substantially reduced long-term growth in soft agar and the number of 3D colonies remained at almost undetectable levels, even after 5 weeks of culture in drug-free medium (Fig. 3D ). These results indicate that even a relatively short-term treatment can yield a sustained anti-tumor effect.
Nitisinone treatment also improved the tumor-suppressive potential of chemotherapy in vivo. HepG2 cells were subcutaneously transplanted into BALB/c nude mice, and were allowed to grow until tumor reached a comparable size prior to receiving DXR/5-FU regimen with or without Nitisinone. Nitisinone alone gradually eliminated CD13 + cells within 8 days ( Fig. 3E ).
Consequently, the combined treatment significantly postponed the time to recurrence (by >21 weeks vs. mice receiving FOLFOX alone) ( Fig. 3F and G).
Tyr metabolism feeds mitochondrial acetyl-CoA into the TCA cycle
In Tyr degradation pathway, 4-FAA is catabolized by FAH to yield end-products, fumarate and acetoacetate, after which the latter is converted into acetyl-CoA (S1C Fig clear upregulation of mitochondrial ROS in CD13 + cells, accompanied with decreased levels of reduced glutathione ( Fig. 4H ). Therefore, HPD inhibition by Nitisinone severely impaired redox balance and energy control in CD13 + CSCs, thereby eliminating this fraction.
Tyr metabolism provides nuclear acetyl-CoA for CBP-dependent Foxd3 acetylation to prevent its MDM2-mediated degradation
Nanoflow liquid chromatography-mass spectrometry analysis indicated that nuclear acetyl- Table) . No 13 C-acetyl peptides corresponding to known acetylation sites on core histones were discovered. Notably, Foxd3 knockdown impaired the resistance of CD13 + cells to 5-FU or SR to a greater extent than with knockdown of any other candidate proteins and Foxd3 (Fig. 5C ). Transduction of CD13 + cells with shRNA targeting CBP abrogated Foxd3 acetylation ( Fig. 5D ). Previous studies reported that MAPK/ERK kinases could increase CBP acetyltransferase activity by phosphorylating CBP at its C-terminal [19] . Since signaling via ERK1/2 lies downstream of the CD13/MAPK axis [20] , treatment of CD13 + cells with CD13
shRNA decreased the level of the CBP-Foxd3 complex and blocked Foxd3 acetylation ( Fig.   5E ), which were largely rescued by a constitutively active ERK mutant (Fig. 5E ). These data suggested that ERK1/2 signaling is required for CBP-Foxd3 interaction and Foxd3 acetylation.
Tandem mass spectrometry analysis of Flag-tagged Foxd3 identified an acetylation site at K181 (S3F Fig) . Acetylation was evident in CD13+ cells with wild-type Foxd3 (wtFoxd3) but not the acetylation-resistant K181A or K181R mutant ( Fig. 5F ). Incidentally, both K181 mutants were subjected to degradation and became undetectable within 12 hours of ectopic expression ( Fig. 5G ). Treatment with the proteasomal inhibitor MG132 increased the stability of K181 mutants ( Fig. 5G ), indicating that these mutants are degraded through the ubiquitinproteosome system. ERK activation leads to FOXO proteins ubiquitination mediated by MDM2 E3 ligase [21] . We found that endogenous Foxd3 binds to MDM2 upon Tyr deprivation ( of HA-tagged MDM2 with wtFoxd3 in HEK293T cells (due to negligible endogenous CBP activity), but not with K181Q ( Fig. 5L ).
Lack of Foxd3 impairs self-renewal and quiescence of CD13+ cells
Next, we examined the role of Foxd3 in the maintenance of CD13+CSCs. In a tumorsphere experiment, Foxd3 knockdown (Foxd3KD) with a shRNA (S5A Fig) could impair self-renewal of CD13 + cells, as reflected by significantly reduced tumorspheres formation ( Fig. 6A and B) and decreased passaging and expansion ( Fig. 6C ). Next, we gave mice limiting doses of Quiescence protects stem cells against loss of self-renewal capacities [22] . In our experiments, Hoechst/PyroninY staining revealed that Foxd3KD in CD13 + cells decreased the percentage of cells in the G0 phase, and increased the proportion in G1/S/G2M phases ( Fig. 6E ). Accordingly, CD13 + cells proliferated faster after Foxd3KD (Fig. 6F ). These data indicated that increased proliferation likely contributes to the reduced self-renewal of Foxd3KD cells by diminishing Korean Cancer Association This article is protected by copyright. All rights reserved.
the pool of quiescent stem cells.
Discussion
Most tumor therapies, including chemo-or targeted-therapies and ionizing radiation, preferentially affect cycling cells but spare quiescent cells. Here we showed that functionally defined CD13 + CSCs in HCCs are characterized as quiescent and do not respond to chemotherapeutic agents. Drug sensitivity is, therefore, a functional property that varies between the heterogeneous cell types comprising HCCs. As stem cell signature expression in various tumor correlates inversely with outcome [23] , we proposed that the degree of CD13 at the gene or protein level relates to the size of the clinically essential pool that can cause relapse.
One strategy towards eliminating quiescent cancer cells is to selectively target unique metabolic demands of these cells [24] . In addition to changes in the metabolism of glucose and glutamine, the role of amino acids in supporting tumor growth has also been increasingly implicated. Using in vivo negative-selection RNAi screens, Possemato et al. [25] established that the serine pathway is essential to most estrogen negative breast cancers subtypes. presence of CD13-induced signaling cascade, which constituted a unique mechanism to regulate the metabolic switch from glycolysis to Tyr degradation. Tyrosine, a non-essential amino acid, can be degraded into acetyl-CoA and fumarate to support citric acid cycle. Thus, CD13 + CSCs depend on mitochondrial function, but not glycolysis, to meet their energy demands. As mitochondrial respiration is the major cellular process that produces ROS, our findings converge on previous reports that CD13 + CSCs have relatively higher ROS than in their CD13-counterparts [8, 27] . 
Cell proliferation assay
Cell proliferation rate was determined by XTT cell proliferation assay (Roche Diagnostics 
Apoptosis analysis
Cells were stained in binding buffer, propidium iodide (PI) and FITC-conjugated Annexin V as provided by the Annexin-V-FLUOS Staining Kit (Roche Diagnostics) according to manufacturer's instructions. Analysis was determined by a FACSCalibur flow cytometer and CellQuest software (BD Biosciences).
3D Organoid Culture
To generate 3D organoids, each piece of the biopsies was rinsed in saline (0.9% NaCl) as the average number of ≥50 μm spherical structures at day 14 that was divided by the total number of cells seeded in each well at day 0. When indicated, 3D organoids were grown in the presence or absence of 5-FU or sorafenib at indicated concentrations after organoid structure was established at day 8. Isolated organoids were dissociated by incubation with 0.25%
Trypsin-EDTA, Y27632 and DNase I (1010415901, Sigma-Aldrich) into single cell suspensions and passaged.
Western blotting
Quantified protein lysates were resolved on SDS-PAGE gel, transferred onto PVDF membrane (Millipore, Billerica, MA) and immunoblotted with the indicated primary antibodies Korean Cancer Association This article is protected by copyright. All rights reserved. The HRP-conjugated secondary antibodies (#7076, #7074 and #7077) used for Western blot were from Cell Signaling Technologies.
Immunoprecipitation
Cells were collected and lysed in lysis buffer supplemented with protease inhibitors, incubated on ice for 15min, and cleared by centrifugation at 8000×g at 4°C for 15minutes. Total protein lysates were subjected to immunoprecipitation with the agarose-immobilized antibody (0.01mg of anti-Foxd3, CBP, Flag, HA, MDM2, acetylated lysine antibody, or isotype control antibody) for overnight at 4°C.
Plasmids construction
The 
In vivo infusions of 13 C-labeled nutrients and isolation of CD13 + , CD13fractions from dissected tumors
Tracer studies were performed in BALB/c nude mice bearing HepG2 xenografts. Three mice in each group were infused with 13 sorted using a FACSAria cell sorter (BD Bioscences) and collected separately in two flow tubes for subsequent mass spectrometry-based analysis of metabolite abundance. were lysed with 10-20 passages through an 18-gauge needle at high setting for 10-15sec with 30sec pauses whilst being kept on ice throughout. The lysate was centrifuged at 9,000g for Korean Cancer Association This article is protected by copyright. All rights reserved.
Subcellular fractionation and fractionation validation
30min (at 4°C), the resultant supernatant was the final "nuclear fraction". Cytosolic and mitochondrial fractions were extracted from S0 by centrifugation at 800g for 10 min. The supernatant S2 was then centrifuged at 11,000g for 10 min to produce the supernatant S3
(containing cytosol and microsomal fraction) and the pellet P3 (containing mitochondrial fraction). The supernatant S3 was precipitated in cold 100% acetone at -20°C for at least 1 hour followed by centrifugation at 12,000g for 5min, the pellet (P4) was then resuspended in 100-300μl STM buffer and labelled as "cytosolic fraction" that likely included some microsomal content. Meanwhile, the pellet P3 was resuspended in 100-200μl STM buffer and centrifuged at 11,000g for 10 min. Once centrifuged, supernatant was discarded, the mitochondrial pellet 
Mass spectrometry for intermediates in Tyr metabolism.
For metabolite collection, media from biological triplicates was fully aspirated and 4 mL of 80% (v/v) methanol was added at dry ice temperatures. Cells and the metabolite-containing supernatants were collected into conical tubes. Insoluble material in lysates was centrifuged at 2,000g for 15 minutes, and the resulting supernatant was evaporated using a refrigerated Korean Cancer Association This article is protected by copyright. All rights reserved.
SpeedVac. Samples were re-suspended using 20 mL HPLC grade water for mass spectrometry. 
Isotopomer data analysis
The extent of isotopic labeling for each metabolite was determined by dividing the summed peak height ion intensities of all labeled species by the ion intensity of both labeled and unlabeled species, expressed in percent. Label-specific ion counts were corrected for naturally occurring 13 labeled species was determined by dividing the peak height ion intensity of each isotopic form (corrected for naturally occurring 13 C species as above) by the summed peak height ion intensity of all labeled species.
Glucose uptake assay
Glucose uptake assay was performed using Wako Glucose kit according to manufacturer's protocol.
Lactate secretion
Lactate secretion was determined using Trinity Lactate Kit according to manufacturer's protocol.
Histone preparation for mass spectrometry
Histone extraction was performed using the commercially available EpiQuik Global Histone Acetylation Assay kit (Epigentek). Briefly, isolated nuclei and whole cells were lysed and proteins were precipitated with 25% trichloracetic acid. Extracted histone pellets were dissolved in HPLC-grade distilled water.
Mass spectrometry for protein acetylation
Protein was resolved by SDS-PAGE, and the band to be analyzed was excised from the gel by the use of a razor blade and divided into ~1mm 3 pieces. Gel pieces were destained using 100mM ammonium bicarbonate (pH8.9) in 50% acetonitrile and then treated with 100μL of 
Sphere formation assays
Cells were resuspended in serum-free medium in DMEM/F12 medium (Invitrogen) containing 20ng/mL EGF (Sigma-Aldrich), 10ng/mL FGF2 (Sigma-Aldrich), B27 (GIBCO), and ITSS (Roche). Cells were plated onto ultralow attachment plates (Corning). Every three days, 200μl DMEM/F12 medium containing EGF, FGF2 was added. Seven days after seeding, the number of spheroids was measured under a microscope. For serial passage of spheres, tumor spheres were dissociated into single-cell suspension and passaged at a ratio of 1: 3 and cultured under conditions described above, after which new tumor spheres formed within 1 week were counted.
Limiting dilution analysis
For in vivo limiting dilution assays, transduced CD13 + cells were dissociated into single cells or diluted serially to the desired cell doses. Cells were injected subcutaneously in the Korean Cancer Association This article is protected by copyright. All rights reserved.
axillary region of the right chest in BALB/c nude mice, and the number of tumors formed out of the number of sites injected was scored to determine the frequency of CSCs calculated using the ELDA software.
Cell cycle analysis
FACS-sorted CD13 + CSCs were incubated for 45 minutes at 37°C with 20μg/ml Hoechst 33342 (Invitrogen) in DMEM/F12 medium containing 20ng/ml EGF (Sigma-Aldrich), 10ng/ml FGF2 (Sigma-Aldrich), B27 (GIBCO), and ITSS (Roche). Pyronin Y (Sigma-Aldrich) was then added at 1μg/mL, and the cells were incubated for another 15 min at 37°C, washed, and immediately analyzed using a MoFlow cytometer (Cytomation) and FlowJo program (Cytomation).
3D Matrigel differentiation assay
For 3D Matrigel cultures, trypsin-dissociated spheroid cultures were dissolved in ice cold, liquid Matrigel and allowed to solidify at 37°C before addition of CSC culture medium.
Treatment were added to the 3D Matrigel cultures 2 days thereafter and continued for 4 days.
Quantification of differentiated spheres was performed by three independent observers that were blinded for the treatment. 
